Best confirmed hematologic responses to bortezomib in patients treated at the recommended doses on each schedule or at lower doses on either schedule
| . | Recommended dose groups . | Lower doses . | |
|---|---|---|---|
| 1.6 mg/m2 QW . | 1.3 mg/m2 BIW . | ||
| Best confirmed hematologic response, n (%) (95% CI) | N = 16 | N = 33 | N = 18 |
| Overall response rate (CR + PR) | 11 (68.8) (41.3-89.0) | 22 (66.7) (48.2-82.0) | 7 (38.9) (17.3-64.3) |
| CR | 6 (37.5) (15.2-64.6) | 8 (24.2) (11.1-42.3) | 2 (11.1) (1.4-34.7) |
| SD | 4 (25.0) (7.3-52.4) | 10 (30.3) (15.6-48.7) | 11 (61.1) (35.7-82.7) |
| PD | 1 (6.3) (0.2-30.2) | 1 (3.0) (0.1-15.8) | 0 |
| Median time to hematologic response, mo (range) | N = 11 | N = 22 | N = 7 |
| First response | 2.1 (0.9-6.9) | 0.7 (0.3-4.0) | 1.2 (0.6-4.8) |
| Best response | 3.2 (0.9-7.2) | 1.2 (0.3-7.6) | 1.2 (0.6-4.8) |
| Duration of response ≥ 1 year, % (95% CI) | 78.8 (38.1-94.3) | 75.5 (41.6-91.4) | 83.3 (27.3-97.5) |
| Time to hematologic disease progression | N = 18 | N = 34 | N = 18 |
| Median follow-up, mo | 17.5 | 8.4 | 9.9 |
| Patients progressing, n | 4 | 5 | 4 |
| 1-year progression-free rate, % (95% CI) | 72.2 (48.7-95.7) | 74.6 (54.4-94.8) | 88.5 (73.6-100) |
| . | Recommended dose groups . | Lower doses . | |
|---|---|---|---|
| 1.6 mg/m2 QW . | 1.3 mg/m2 BIW . | ||
| Best confirmed hematologic response, n (%) (95% CI) | N = 16 | N = 33 | N = 18 |
| Overall response rate (CR + PR) | 11 (68.8) (41.3-89.0) | 22 (66.7) (48.2-82.0) | 7 (38.9) (17.3-64.3) |
| CR | 6 (37.5) (15.2-64.6) | 8 (24.2) (11.1-42.3) | 2 (11.1) (1.4-34.7) |
| SD | 4 (25.0) (7.3-52.4) | 10 (30.3) (15.6-48.7) | 11 (61.1) (35.7-82.7) |
| PD | 1 (6.3) (0.2-30.2) | 1 (3.0) (0.1-15.8) | 0 |
| Median time to hematologic response, mo (range) | N = 11 | N = 22 | N = 7 |
| First response | 2.1 (0.9-6.9) | 0.7 (0.3-4.0) | 1.2 (0.6-4.8) |
| Best response | 3.2 (0.9-7.2) | 1.2 (0.3-7.6) | 1.2 (0.6-4.8) |
| Duration of response ≥ 1 year, % (95% CI) | 78.8 (38.1-94.3) | 75.5 (41.6-91.4) | 83.3 (27.3-97.5) |
| Time to hematologic disease progression | N = 18 | N = 34 | N = 18 |
| Median follow-up, mo | 17.5 | 8.4 | 9.9 |
| Patients progressing, n | 4 | 5 | 4 |
| 1-year progression-free rate, % (95% CI) | 72.2 (48.7-95.7) | 74.6 (54.4-94.8) | 88.5 (73.6-100) |
QW indicates once weekly; BIW, twice weekly; CR, complete response; PR, partial response; SD, stable disease; and PD, progressive disease.